The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors
  • The agreements with Deakin University’s Institute for Frontier Materials (DIFM) and Swinburne university of Technology will progress the commercialisation of the Tn Antigen biosensor and the development of other biosensors using UBI’s electrochemical platform technology
  • UBI has contracted Dr Wren Green and Dr Saimon Moraes Silva to work on the project, with fees falling collectively under $300,000 per annum
  • Universal Biosensors shares are up 9.68 per cent, trading at 68 cents

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.

The agreements with Deakin University’s Institute for Frontier Materials (DIFM) and Swinburne University of Technology will progress the commercialisation of the Tn Antigen biosensor, used for the detection, staging and monitoring of cancer, as well as the development of other biosensors using UBI’s electrochemical platform technology.

The Deakin University agreement contracts 50 per cent of the of Senior Fellow Dr Wren Green’s time and resources to UBI. The agreement is for a five-year term, for a fixed fee.

The Swinburne agreement contracts 80 per cent of Dr Saimon Moraes Silva’s time, also under a fixed fee, ending in February 2022. Dr Saimon will work under the supervision of Professor Simon Moulton of Swinburne’s School Software and Electrical Engineering and Iverson Health Innovation Research Institute.

Both agreements have fees payable by UBI, collectively coming under $300,000 per year.

“Using UBI’s platform technology we plan to deliver a cancer biosensor capable of identifying, staging and monitoring cancer from a finger prick of blood, using a portable hand held device,” said CEO of UBI John Sharman.

“The knowledge and resources of DIFM and Swinburne will help deliver this as well as fast track the development of other biosensors we are working on.”

Universal Biosensors shares are up 9.68 per cent, trading at 68 cents at 1:15 pm AEST.

UBI by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…